Response to the feasibility of Kreher et al's "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors"

Katelyn J Rypka; Noah Goldfarb; Matthew Mansh

doi:10.1016/j.jaad.2023.05.095

Response to the feasibility of Kreher et al's "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors"

J Am Acad Dermatol. 2023 Oct;89(4):e181-e185. doi: 10.1016/j.jaad.2023.05.095. Epub 2023 Jun 26.

Authors

Katelyn J Rypka¹, Noah Goldfarb¹, Matthew Mansh²

Affiliations

¹ Department of Dermatology, University of Minnesota Medical School, Minneapolis, Minnesota; Department of Dermatology, Minneapolis VA Medical Center, Minneapolis, Minnesota.
² Department of Dermatology, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: Mansh@umn.edu.

PMID: 37379901
DOI: 10.1016/j.jaad.2023.05.095

No abstract available

Keywords: basal cell carcinoma; immunosuppression; inflammatory bowel disease; keratinocyte skin cancer; nonmelanoma skin cancer; primary skin cancer; psoriasis; rheumatoid arthritis; skin cancer screening; squamous cell carcinoma.

Publication types

Letter
Comment

MeSH terms

Alkylating Agents
Biological Products*
Feasibility Studies
Humans
Immunosuppressive Agents
Melanoma* / drug therapy
Methotrexate / therapeutic use
Skin Neoplasms* / drug therapy
Skin Neoplasms* / epidemiology

Substances

Methotrexate
Immunosuppressive Agents
Biological Products
Alkylating Agents